Stock Market

Azitra Completes IPO, Pricing 1.5 Million Shares at $5 per Share

Azitra, Inc. Prices Initial Public Offering at $5.00 per Share

Biopharmaceutical company Azitra, Inc. (NYSE American: AZTR) has announced the pricing of its initial public offering (IPO), with 1,500,000 shares of common stock offered at a price of $5.00 per share. The IPO is expected to generate aggregate gross proceeds of $7,500,000, before deducting underwriting discounts and other offering expenses. Additionally, the underwriters have been granted a 45-day option to purchase up to an additional 225,000 shares of common stock to cover over-allotments. Trading of the common stock is scheduled to begin on the NYSE American under the ticker symbol “AZTR” on June 16, 2023, and the offering is set to close on June 21, 2023, subject to customary closing conditions.

The net proceeds from the IPO will be utilized by Azitra for various purposes, including clinical trials, product development, research and development, clinical manufacturing, working capital, and general corporate purposes. ThinkEquity is acting as the sole book-running manager for the offering.

The offering is being made in accordance with a registration statement on Form S-1, which has been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on June 15, 2023. Interested individuals can obtain electronic copies of the final prospectus from ThinkEquity. The prospectus will also be available on the SEC’s website.

This press release does not constitute an offer to sell or a solicitation of an offer to buy securities and is subject to registration or qualification under the securities laws of the relevant jurisdiction.

About Azitra, Inc. Azitra, Inc. is an early-stage clinical biopharmaceutical company specializing in the development of innovative therapies for precision dermatology. The company focuses on engineered proteins and topical live biotherapeutic products. Azitra has established a proprietary platform comprising a microbial library with approximately 1,500 unique bacterial strains, which are screened for their therapeutic characteristics. The company incorporates artificial intelligence and machine learning technology to analyze and predict the drug-like molecules in its strain library. Azitra’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis for dermatologic therapies.

Forward-Looking Statements This press release contains forward-looking statements, which are subject to substantial risks and uncertainties. These statements are based on Azitra, Inc.’s current expectations and may include words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or similar expressions. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those anticipated, and they are based on assumptions about future events that may not prove to be accurate. Detailed information regarding the risks and uncertainties associated with the offering can be found in the “Risk Factors” section of the final prospectus filed with the SEC. The forward-looking statements in this announcement are made as of the date of this release, and Azitra, Inc. undertakes no obligation to update such information except as required by law.

CONTACT Norman Staskey Danforth Advisors [email protected]

Azitra logo

CisionView original content to download multimedia:

SOURCE Azitra, Inc.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button